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More on Transfusion and Adverse Outcome
It’s Time to Change
P REOPERATIVE anemia and perioperative allogeneicerythrocyte (RBC) transfusion have both been shown
to be independently associated with adverse outcome, such as
increased mortality, postoperative infections, lung and kid-
ney injury, myocardial infarction, stroke, and increased
length of hospital stay.1–6 The relative contribution of each
of these conditions, and their interactions, is difficult to spec-
ify. The study by Glance et al. in this issue of ANESTHESIOL-
OGY is important, because the authors studied more than
10,000 patients with preoperative anemia who underwent
elective noncardiac surgery and received up to 2 units of
RBCs intraoperatively. The study used records from the
AmericanCollege of SurgeonsNational Surgical Quality Im-
provement Program (ACS NSQIP) database.7
In an attempt to reduce confounders, the investigators
included only patients within a preoperative hemoglobin
range of 6–10 g/dl. In this hemoglobin range, according to
American Society of Anesthesiologists guidelines, RBC
transfusions may be administered on a clinical basis.8 Thus,
these RBC transfusions had likely occurred after limited blood
loss. Observed outcomes thusmay be attributedmore clearly to
RBC transfusion than if patients had started with normal pre-
operative hemoglobin and, as a consequence, had to have lost
large amounts of blood during ill-controlled surgery before be-
ing transfused. In the latter case, it would be difficult to say
whether the adverse outcomes were due to hemodynamic insta-
bility and other effects of acute blood loss or due to the RBC
transfusion itself. Since in the study byGlance et al.7 all patients
were anemic preoperatively andmay not have experiencedmas-
sive blood loss before the index transfusion, the observed out-
comes may be attributed quite clearly to the RBC transfusion
administered. Also, the negative impact on outcome was sub-
stantial: Transfusion of only 1 or 2 units of RBCs resulted in
more septic (odds ratio [OR]: 1.43), pulmonary (OR: 1.79),
thromboembolic (OR: 1.77), and wound (OR: 1.87) compli-
cations and increased mortality (OR: 1.29).
The key strengths of this study lie in the number of the
patients and the detailed data collection; the shortcomings
are shared with many other transfusion cohort studies. De-
spite various efforts, it is always difficult to call transfusion as
the cause of an adverse outcome, as opposed to some other
associated patient comorbidity. A brief look at table 1 of the
Glance et al. article indicates that the transfused cohort was
generally in worse shape at baseline, compared with the not-
transfused group (lower hematocrit, older age, more depen-
dent, more comorbidities, etc.). Statistical methods are used
to remedy this commonly seen disparity. Multivariate anal-
ysis can be used to adjust for confounders (the method used
in the current study), or transfused patients can be matched
against nontransfused patients (with varying degrees of com-
plexity). Although these approaches often do marvels, they
are not “cures,” because they are ultimately limited by the
available variables and their data. Dowe have all the potential
confounders captured in our dataset? How certain are we of
the primary reasons behind giving transfusion to every single
case? What was the tipping point that made the physician
decide to give blood to this patient, but not the other patient?
These questions are often impossible to answer accurately in
cohort studies, and they undermine the validity of the results.
Although themultivariate adjustment used in this study is
a valid method, more data on the models would have been
helpful (e.g., strength of association as indicated by pseudo-
R-squared or the reasoning behind creating the specific he-
matocrit categories). In addition, use of a matching approach
may have allowed for more transparent interpretation of the
results (at expense of reduced sample size). Given the large
sample size, it would have been interesting to see whether the
transfused and not-transfused patients could have been effec-
tively matched to each other based on the risk factors for
receiving transfusions (and, possibly, known risk factors of
each outcome), thus allowing a more direct comparison.
In addition, large database analyses do have limitations of
their own. Problems with miscoding of procedures and diag-
noses are well recognized.9 This study by Glance et al., how-
ever, relies on the NSQIP database, which is more accurate
than other state or federal administrative datasets. Data are
collected by trained surgical chart reviewers, and participat-
ing hospitals undergo interrater reliability audits.10 Still, for
any particular study, a generalized database such as NSQIP
will not provide all the information that one might wish for.
In the case of the present study, we do not know the extent
of pre- or postoperative transfusion in the study patients;
because of NSQIP data definitions, patients could have re-
ceived up to 4 units preoperatively and 4 units postopera-
tively. Transfusion before or after surgery, but not during,
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might decrease the detected effect of intraoperative transfu-
sion; alternatively, those patients requiring pre- or postoper-
ative transfusion might be more likely to receive blood intra-
operatively. NSQIP does not record intraoperative nadir
hematocrit or immediate postoperative hematocrit. Thus, we
do not know if lower intraoperative hematocrit was associ-
ated with worse outcome. Because NSQIP data do not in-
clude a hospital identifier, the final results may have been
confounded by hospital-based differences in practice, includ-
ing differences in local transfusion triggers.10
Results of the present study are in line with previous stud-
ies in general,3 cardiac,1 orthopedic,4 and trauma surgery.5,6
Also, in a recent cohort data analysis in 239,286 elderly Vet-
erans Administration patients with and without preoperative
anemia RBC transfusions resulted in increased 30-day mor-
tality (adjusted OR: 1.37 [1.27–1.48]).11 Only in a 1-min
subgroup of patients with a preoperative hematocrit of less
than or equal to 24% (1.9% of the study population) did
RBC transfusion result in a reduced mortality, whereas in
patients with a preoperative hematocrit of greater than 30%
(more than 80% of the study population), RBC transfusions
actually increased mortality significantly (ORs: 1.37–1.59).
Interestingly, in patients who eventually died, late postoper-
ative complications, such as failure to wean from the venti-
lator and unplanned intubation indicative of lung injury,
renal failure, and infectious complications, were very similar
to the ones found in the article by Glance et al.,7 and they
were more frequent than in nontransfused patients.11
Another aspect of the study by Glance et al.7 deserves
mentioning, namely the fact that nonelective cases were ex-
cluded. Therefore, it should have been possible to treat pre-
existing anemia before surgery. This is important, because
preoperative anemia is frequent,2,11–13 easy to detect,
and—in many situations—treatable at relatively low costs.14
At least, in orthopedic surgery, there is strong evidence that
preoperative treatment of anemia results not only in reduced
RBC transfusion, but also in improved outcome.15
Where do we go from here? The call for prospective,
randomized studies on the benefit or detriment of allogeneic
RBC transfusions is the usual conclusion after studies of the
likes of Glance et al. are published. This conclusion is cer-
tainly politically correct; however, if Glance et al. and the
slew of others are correct—which is a valid possibility—can we
take the responsibility to continue today’s widespread transfu-
sion practice, an approach that is putting patients at risk?
Contrarians to the above still overly rely on banked blood
products, despite mounting evidence that patient blood
management is achievable, avoids exposure to allogeneic
blood products, improves patient outcome, and saves re-
sources.15,16 The ease of ignoring preoperative anemia as well
as the simplicity of ordering and transfusing RBCs and thereby
completely ignoring the burgeoning evidence of adverse trans-
fusion outcome are not in the best interest of patients. Main-
taining the clinical status quo under such circumstances would
not be accepted in any other field of medicine in the context of
current safety and quality standards.
Working on studies regarding benefit or detriment of
allogeneic RBC transfusions is important, but more so is
acting already today according to patient blood management
principles; it is time for a change toward better patient care.
Donat R. Spahn, M.D., F.R.C.A.,* Aryeh Shander, M.D.,
F.C.C.P., F.C.C.M.,† Axel Hofmann, M.E.,‡ Mitchell F. Ber-
man, M.D., M.P.H.§ * Institute of Anesthesiology and Head
Medical, Section Anesthesiology, Intensive Care Medicine and
OR-Management, University Hospital Zurich, Zurich, Switzer-
land. donat.spahn@usz.ch. † Department of Anesthesiology
and Critical Care and Hyperbaric Medicine and Institute for
Patient Blood Management and Bloodless Medicine and Sur-
gery, Englewood Hospital and Medical Center, Englewood,
New Jersey. ‡ Medical Society for Blood Management, Laxen-
burg, Austria, and Center for Population Health Research, Cur-
tin University, Western Australia. §Department of Anesthesiol-
ogy, Columbia University College of Physicians and Surgeons,
New York, New York.
References
1. Karkouti K, Wijeysundera DN, Beattie WS: Risk associated
with preoperative anemia in cardiac surgery: A multicenter
cohort study. Circulation 2008; 117:478–84
2. Beattie WS, Karkouti K, Wijeysundera DN, Tait G: Risk associated
with preoperative anemia in noncardiac surgery: A single-center
cohort study. ANESTHESIOLOGY 2009; 110:574–81
3. Bernard AC, Davenport DL, Chang PK, Vaughan TB, Zwisch-
enberger JB: Intraoperative transfusion of 1 U to 2 U packed
red blood cells is associated with increased 30-day mortality,
surgical-site infection, pneumonia, and sepsis in general sur-
gery patients. J Am Coll Surg 2009; 208:931–7
4. Pedersen AB, Mehnert F, Overgaard S, Johnsen SP: Alloge-
neic blood transfusion and prognosis following total hip
replacement: A population-based follow up study. BMC Mus-
culoskelet Disord 2009; 10:167
5. Charles A, Shaikh AA, Walters M, Huehl S, Pomerantz R:
Blood transfusion is an independent predictor of mortality
after blunt trauma. Am Surg 2007; 73:1–5
6. Chaiwat O, Lang JD, Vavilala MS, Wang J, MacKenzie EJ,
Jurkovich GJ, Rivara FP: Early packed red blood cell transfu-
sion and acute respiratory distress syndrome after trauma.
ANESTHESIOLOGY 2009; 110:351–60
7. Glance LG, Dick AW, Mukamel DB, Fleming FJ, Zollo RA,
Wissler R, Salloum R, Meredith W, Osler TM: Association
between intraoperative blood transfusion and mortality and
morbidity in patients undergoing noncardiac surgery. ANES-
THESIOLOGY 2011; 114:283–92.
8. Practice guidelines for perioperative blood transfusion and
adjuvant therapies: An updated report by the American So-
ciety of Anesthesiologists Task Force on Perioperative Blood
Transfusion and Adjuvant Therapies. ANESTHESIOLOGY 2006;
105:198–208
9. Woodworth GF, Baird CJ, Garces-Ambrossi G, Tonascia J, Tamargo
RJ: Inaccuracy of the administrative database: Comparative analy-
sis of two databases for the diagnosis and treatment of intracranial
aneurysms. Neurosurgery 2009; 65:251–6
10. Gombotz H, Rehak PH, Shander A, Hofmann A: Blood use in
elective surgery: The Austrian benchmark study. Transfusion
2007; 47:1468–80
11. WuWC, Smith TS, Henderson WG, Eaton CB, Poses RM, Uttley G,
Mor V, Sharma SC, Vezeridis M, Khuri SF, Friedmann PD: Opera-
EDITORIAL VIEWS
Anesthesiology 2011; 114:234–6 Spahn et al.235
tive blood loss, blood transfusion, and 30-day mortality in older
patients after major noncardiac surgery. Ann Surg 2010; 252:
11–7
12. Shander A, Knight K, Thurer R, Adamson J, Spence R: Prevalence
and outcomes of anemia in surgery: A systematic review of the
literature. Am J Med 2004; 116(Suppl 7A):58–69S
13. Goodnough LT, Vizmeg K, Sobecks R, Schwarz A, Soegiarso
W: Prevalence and classification of anemia in elective ortho-
pedic surgery patients: Implications for blood conservation
programs. Vox Sang 1992; 63:90–5
14. Goodnough LT, Shander A, Spivak JL, Waters JH, Friedman
AJ, Carson JL, Keating EM, Maddox T, Spence R: Detection,
evaluation, and management of anemia in the elective surgi-
cal patient. Anesth Analg 2005; 101:1858–61
15. Spahn DR: Anemia and patient blood management in hip and
knee surgery: A systematic review of the literature. ANESTHE-
SIOLOGY 2010; 113:482–95
16. Moskowitz DM, Klein JJ, Shander A, Cousineau KM, Gold-
weit RS, Bodian C, Perelman SI, Kang H, Fink DA, Rothman
HC, Ergin MA: Predictors of transfusion requirements for
cardiac surgical procedures at a blood conservation center.
Ann Thorac Surg 2004; 77:626–34
Editorial Views
Anesthesiology 2011; 114:234–6 Spahn et al.236
